1. Scrip
  3. >>Anti-infective

Bugs As Drugs: The Budding Microbiome Modulator Pipeline

 
• By Ayisha Sharma

INFOGRAPHIC: The sheer number of micro-organisms in the human body and their functions makes the microbiome a ripe target for therapeutic intervention. While still rather early, data show the microbiome modulator pipeline has immense potential across a range of therapeutic areas, not just in gastrointestinal disease.  

Biofilm - Microbiome - Abstract Illustration.
Eighty Percent Of Cellular Immunity Is Present In The Intestine • Source: Alamy

The human microbiome is a relatively novel area of therapeutic exploration. The collective term for the micro-organisms that exist within the human body, particularly in the gastrointestinal system and the skin, the microbiome serves a range of functions including aiding the metabolic processes, protecting against pathogens and interacting with the immune system. (Also see "‘Bugs As Drugs’ Approach To Cancer Nears Advanced Development" - In Vivo, 19 January, 2022.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.